Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The company’s innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs.
Two programs have advanced to the clinical stage:
(1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China
(2) neurovascular AMD (wet AMD) rAAV gene therapy in USA
The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids.
Exegenesis Bio has raised over $150 M since inception in 2019 and currently employs over 200 scientific and operations staff worldwide.
Website: https://www.exegenesisbio.com/
Contacts:
Company Information: Contact@ExegenesisBio.com
Business Development: BD@ExegenesisBio.com
Careers: Careers@ExegenesisBio.com
Company Details
- Employees
- 16
- Founded
- -
- Address
- Philadelphia, Pa, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.exegenesisbio.com/
- Keywords
- Gene Therapy, Biotechnology, Cell Therapy, AAV, Spinal Muscular Atrophy, Eye Diseases, Hemophilia, CNS Diseases, Liver-directed Diseases, Manufacturing, Lentivirus.
- HQ
- Philadelphia, PA
Exegenesis Bio Questions
Exegenesis Bio's website is https://www.exegenesisbio.com/
Exegenesis Bio's LinkedIn profile is https://www.linkedin.com/company/exegenesis
Exegenesis Bio has
16 employees.
View email and phone details for 16
employees at Exegenesis Bio.
Exegenesis Bio's industry is
Biotechnology Research
Exegenesis Bio's top competitors are
Insilicom,
Tevard Biosciences,
Affinia Therapeutics,
Protara Therapeutics,
Ernexa Therapeutics,
Voyager Therapeutics, Inc.,
Mesoblast Limited,
Amarna Therapeutics,
Adaptimmune,
Nkarta, Inc..
Exegenesis Bio's categories are Biotechnology Research
Exegenesis Bio's founding year is 2019
